Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Study sponsor: Veru Inc. · VERU
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-04Actual
Enrollment · participants105Actual
Source updated2024-02-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.